Literature DB >> 17804713

Expression of a CALM-AF10 fusion gene leads to Hoxa cluster overexpression and acute leukemia in transgenic mice.

David Caudell1, Zhenhua Zhang, Yang Jo Chung, Peter D Aplan.   

Abstract

To assess the role of the CALM-AF10 fusion gene in leukemic transformation in vivo, we generated transgenic mice that expressed a CALM-AF10 fusion gene. Depending on the transgenic line, at least 40% to 50% of the F(1) generation mice developed acute leukemia at a median age of 12 months. Leukemic mice typically had enlarged spleens, invasion of parenchymal organs with malignant cells, and tumors with myeloid markers such as myeloperoxidase, Mac1, and Gr1. Although most leukemias were acute myeloid leukemia, many showed lymphoid features, such as CD3 staining, or clonal Tcrb or Igh gene rearrangements. Mice were clinically healthy for the first 9 months of life and had normal peripheral blood hemograms but showed impaired thymocyte differentiation, manifested by decreased CD4(+)/CD8(+) cells and increased immature CD4(-)/CD8(-) cells in the thymus. Hematopoietic tissues from both clinically healthy and leukemic CALM-AF10 mice showed up-regulation of Hoxa cluster genes, suggesting a potential mechanism for the impaired differentiation. The long latency period and incomplete penetrance suggest that additional genetic events are needed to complement the CALM-AF10 transgene and complete the process of leukemic transformation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17804713      PMCID: PMC1986634          DOI: 10.1158/0008-5472.CAN-06-3749

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

1.  Overexpression of HOXA10 perturbs human lymphomyelopoiesis in vitro and in vivo.

Authors:  C Buske; M Feuring-Buske; J Antonchuk; P Rosten; D E Hogge; C J Eaves; R K Humphries
Journal:  Blood       Date:  2001-04-15       Impact factor: 22.113

2.  Mixed-lineage leukemia with t(10;11)(p13;q21): an analysis of AF10-CALM and CALM-AF10 fusion mRNAs and clinical features.

Authors:  K Kumon; H Kobayashi; N Maseki; A Sakashita; M Sakurai; A Tanizawa; S Imashuku; Y Kaneko
Journal:  Genes Chromosomes Cancer       Date:  1999-05       Impact factor: 5.006

Review 3.  Chromosome translocations: dangerous liaisons revisited.

Authors:  J D Rowley
Journal:  Nat Rev Cancer       Date:  2001-12       Impact factor: 60.716

4.  Molecular analysis of the CALM/AF10 fusion: identical rearrangements in acute myeloid leukemia, acute lymphoblastic leukemia and malignant lymphoma patients.

Authors:  S K Bohlander; V Muschinsky; K Schrader; R Siebert; B Schlegelberger; L Harder; V Schemmel; C Fonatsch; W D Ludwig; W Hiddemann; M H Dreyling
Journal:  Leukemia       Date:  2000-01       Impact factor: 11.528

5.  NUP98-HOXA9 expression in hemopoietic stem cells induces chronic and acute myeloid leukemias in mice.

Authors:  E Kroon; U Thorsteinsdottir; N Mayotte; T Nakamura; G Sauvageau
Journal:  EMBO J       Date:  2001-02-01       Impact factor: 11.598

6.  Identification and molecular characterisation of a CALM-AF10 fusion in acute megakaryoblastic leukaemia.

Authors:  L K Jones; T Chaplin; A Shankar; M Neat; N Patel; D P Samuel; A S Hill; S Debernardi; A Bassini; B D Young; V Saha
Journal:  Leukemia       Date:  2001-06       Impact factor: 11.528

7.  The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10.

Authors:  Jorge F DiMartino; Paul M Ayton; Everett H Chen; Clarissa C Naftzger; Bryan D Young; Michael L Cleary
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

8.  Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia.

Authors:  U Thorsteinsdottir; E Kroon; L Jerome; F Blasi; G Sauvageau
Journal:  Mol Cell Biol       Date:  2001-01       Impact factor: 4.272

9.  Hoxa9 immortalizes a granulocyte-macrophage colony-stimulating factor-dependent promyelocyte capable of biphenotypic differentiation to neutrophils or macrophages, independent of enforced meis expression.

Authors:  K R Calvo; D B Sykes; M Pasillas; M P Kamps
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

10.  Chromosomal translocation master genes, mouse models and experimental therapeutics.

Authors:  T H Rabbitts
Journal:  Oncogene       Date:  2001-09-10       Impact factor: 9.867

View more
  28 in total

1.  Enforced expression of Lin28b leads to impaired T-cell development, release of inflammatory cytokines, and peripheral T-cell lymphoma.

Authors:  Sarah H Beachy; Masahiro Onozawa; Yang Jo Chung; Chris Slape; Sven Bilke; Princy Francis; Marbin Pineda; Robert L Walker; Paul Meltzer; Peter D Aplan
Journal:  Blood       Date:  2012-06-21       Impact factor: 22.113

2.  Isolated Hoxa9 overexpression predisposes to the development of lymphoid but not myeloid leukemia.

Authors:  Sarah H Beachy; Masahiro Onozawa; Deborah Silverman; Yang Jo Chung; Mariela Martinez Rivera; Peter D Aplan
Journal:  Exp Hematol       Date:  2013-02-19       Impact factor: 3.084

3.  Somatic mutations in murine models of leukemia and lymphoma: Disease specificity and clinical relevance.

Authors:  Liat Goldberg; Sheryl M Gough; Fan Lee; Christine Dang; Robert L Walker; Yuelin J Zhu; Sven Bilke; Marbin Pineda; Masahiro Onozawa; Yang Jo Chung; Paul S Meltzer; Peter D Aplan
Journal:  Genes Chromosomes Cancer       Date:  2017-03-31       Impact factor: 5.006

4.  Insulin-like growth factor 1 is a direct HOXA9 target important for hematopoietic transformation.

Authors:  J Steger; E Füller; M-P Garcia-Cuellar; K Hetzner; R K Slany
Journal:  Leukemia       Date:  2014-09-25       Impact factor: 11.528

5.  Up a lymphoid blind alley: Does CALM/AF10 disturb Ikaros during leukemogenesis?

Authors:  Philipp A Greif; Stefan K Bohlander
Journal:  World J Biol Chem       Date:  2011-06-26

6.  Retroviral insertional mutagenesis identifies Zeb2 activation as a novel leukemogenic collaborating event in CALM-AF10 transgenic mice.

Authors:  David Caudell; David P Harper; Rachel L Novak; Rachel M Pierce; Christopher Slape; Linda Wolff; Peter D Aplan
Journal:  Blood       Date:  2009-12-09       Impact factor: 22.113

7.  A CALM-derived nuclear export signal is essential for CALM-AF10-mediated leukemogenesis.

Authors:  Amanda E Conway; Paula B Scotland; Catherine P Lavau; Daniel S Wechsler
Journal:  Blood       Date:  2013-03-13       Impact factor: 22.113

8.  Gene expression profiling and candidate gene resequencing identifies pathways and mutations important for malignant transformation caused by leukemogenic fusion genes.

Authors:  Rachel L Novak; David P Harper; David Caudell; Christopher Slape; Sarah H Beachy; Peter D Aplan
Journal:  Exp Hematol       Date:  2012-08-08       Impact factor: 3.084

9.  The CALM and CALM/AF10 interactor CATS is a marker for proliferation.

Authors:  Leticia Fröhlich Archangelo; Philipp A Greif; Michael Hölzel; Thomas Harasim; Elisabeth Kremmer; Gerhard K H Przemeck; Dirk Eick; Aniruddha Jayant Deshpande; Christian Buske; Martin Hrabé de Angelis; Sara Teresinha Olalla Saad; Stefan K Bohlander
Journal:  Mol Oncol       Date:  2008-09-04       Impact factor: 6.603

Review 10.  The role of CALM-AF10 gene fusion in acute leukemia.

Authors:  D Caudell; P D Aplan
Journal:  Leukemia       Date:  2007-12-20       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.